Go Pro
→ First Look: Elon’s “Starphone” (From Stansberry Research) (Ad)tc pixel
NASDAQ:SCYX

SCYNEXIS Q4 2024 Earnings Report

SCYNEXIS logo
$4.62 +0.23 (+5.24%)
Closing price 04:00 PM Eastern
Extended Trading
$4.60 -0.02 (-0.50%)
As of 08:00 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.
ProfileEarnings HistoryForecast

SCYNEXIS EPS Results

Actual EPS
-$0.72
Consensus EPS
-$1.76
Beat/Miss
Beat by +$1.04
One Year Ago EPS
N/A

SCYNEXIS Revenue Results

Actual Revenue
$0.98 million
Expected Revenue
N/A
Beat/Miss
N/A
YoY Revenue Growth
N/A

SCYNEXIS Announcement Details

Quarter
Q4 2024
Date
3/12/2025
Time
After Market Closes
Conference Call Date
Wednesday, March 12, 2025
Conference Call Time
5:00PM ET

Upcoming Earnings

SCYNEXIS' Q3 2026 earnings is estimated for Wednesday, November 4, 2026, based on past reporting schedules, with a conference call scheduled on Tuesday, November 10, 2026 at 4:00 PM ET. Check back for transcripts, audio, and key financial metrics as they become available.

Conference Call Resources

Powered by Quartr

Earnings Documents

SCYNEXIS's Q4 2024 Press ReleasePress Release
(8-K)
SCYNEXIS's Q4 2024 Annual reportAnnual report
(10-K)

SCYNEXIS Earnings Headlines

Scynexis stock surges on $214M BARDA contract for SCY-247
September 28 at 12:26 PM  |  finance.yahoo.comhttps://finance.yahoo.com/healthcare/articles/scynexis-stock-surges-214m-barda-135830821.html
Scynexis Shares Rise 13.9% After BARDA Awards SCY-247 Development Contract
September 28 at 12:26 PM  |  finance.yahoo.comhttps://finance.yahoo.com/healthcare/articles/scynexis-shares-rise-13-9-121017917.html
First Look: Elon’s “Starphone”
Rumors are swirling that Elon Musk is developing a new mobile device that could rival the iPhone. It's said to be thinner, longer-lasting on battery, and cheaper to produce, with the ability to work worldwide without relying on cell towers. Former Bloomberg reporter and SAC Capital trader Josh Baylin says the evidence is mounting. He notes the FCC recently gave Musk a green light connected to his mobile plans, adding fuel to speculation. Baylin previously called the smartphone boom in 2004 and predicted Apple would sell a billion phones when others expected a fraction of that.tc pixel
September 28 at 1:00 AM  |  Stansberry Research (Ad)
SCYNEXIS Awarded BARDA Contract Providing Up to $214 Million in Non-Dilutive Funding for the Development of SCY-247
September 28 at 7:30 AM  |  globenewswire.comhttps://www.globenewswire.com/news-release/2026/09/28/3369788/0/en/scynexis-awarded-barda-contract-providing-up-to-214-million-in-non-dilutive-funding-for-the-development-of-scy-247.html
SCYNEXIS (NASDAQ:SCYX) Shares Pass Above 50-Day Moving Average - Time to Sell?
September 23, 2026  |  americanbankingnews.comhttps://www.americanbankingnews.com/?p=31041579
SCYNEXIS Appoints Seasoned Industry Veteran Steven K. Burke, M.D., to its Board of Directors
September 22, 2026  |  markets.businessinsider.comhttps://markets.businessinsider.com/news/stocks/scynexis-appoints-seasoned-industry-veteran-steven-k-burke-m-d-to-its-board-of-directors-1036563490
See More SCYNEXIS Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like SCYNEXIS? Sign up for Earnings360's daily newsletter to receive timely earnings updates on SCYNEXIS and other key companies, straight to your email.

About SCYNEXIS

SCYNEXIS (NASDAQ:SCYX) is a biotechnology company focused on developing and commercializing novel antifungal therapies for patients with fungal infections. Its lead product is BREXAFEMME (ibrexafungerp), an oral, non-azole antifungal designed to address certain vaginal and other fungal infections.

BREXAFEMME was approved by the U.S. Food and Drug Administration in 2021 for the treatment of vulvovaginal candidiasis, commonly known as a yeast infection. The product later received an additional U.S. approval for reducing the incidence of recurrent vulvovaginal candidiasis in adult and post-menarchal adolescent females. Ibrexafungerp belongs to a new class of antifungal agents known as triterpenoid antifungals.

SCYNEXIS has historically focused its research and development activities on addressing drug-resistant and difficult-to-treat fungal infections. The company’s commercial activities are primarily centered on the United States, while it has pursued collaborations and licensing arrangements to support the broader development and commercialization of ibrexafungerp.

View SCYNEXIS Profile
Earnings Tools